Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Biotechnology

Health Care

Life Sciences

Therapeutics

Alpha-9 Oncology

David Hirsch

Pau-Lin Ngen

Stephen Mitchener

Julie Rousseau

Matthias Jaffe

Alison Fleming

The Scientific Research Team at Alpha-9 Oncology is responsible for advancing the development of innovative radiopharmaceuticals through comprehensive research and translational biology efforts. This team collaborates to design and optimize molecules that target cancerous tissues, ensuring their safety and efficacy in clinical applications. Leveraging expertise in chemistry, biology, and laboratory management, team members drive the company’s mission to enhance cancer treatment and patient outcomes.

Scientific Research Team

Leadership Team

Scientific Research Team

About

Team members

Other teams at Alpha-9 Oncology

Leadership Team